Market Indices
Sector Heatmap
BMRN — BioMarin Pharmaceuticals Inc
NasdaqBioMarin Pharmaceuticals Inc
- O
- 58.52
- H
- 58.73
- L
- 57.15
- V
- 2.19M
BMRN — Latest News & Headlines
20 StoriesBioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History Yahoo! Finance Canada
BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history - Yahoo Finance UK
BioMarin Pharmaceutical Inc. (BMRN) stock price, news, quote and history Yahoo Finance UK
BMRN Stock Price Prediction 2026-2027 | BioMarin Forecast - 24/7 Wall St.
BMRN Stock Price Prediction 2026-2027 | BioMarin Forecast 24/7 Wall St.
After 4,086 shares were delivered or withheld, BioMarin (BMRN) R&D chief holds 47,732 shares. - stocktitan.net
After 4,086 shares were delivered or withheld, BioMarin (BMRN) R&D chief holds 47,732 shares. stocktitan.net
BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN) - Seeking Alpha
BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN) Seeking Alpha
3 Healthcare Stocks That Fall Short - StockStory
3 Healthcare Stocks That Fall Short StockStory
BioMarin Pharmaceutical (BMRN) Adds Robert Plenge To Its Board - Simply Wall Street
BioMarin Pharmaceutical (BMRN) Adds Robert Plenge To Its Board Simply Wall Street
Discipline and Rules-Based Execution in BMRN Response - Stock Traders Daily
Discipline and Rules-Based Execution in BMRN Response Stock Traders Daily
What BioMarin Pharmaceutical (BMRN)'s AI Drug Discovery Deal Means For Shareholders - Simply Wall Street
What BioMarin Pharmaceutical (BMRN)'s AI Drug Discovery Deal Means For Shareholders Simply Wall Street
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts Yahoo Finance
BioMarin Pharmaceutical stock holds near a $12.38 billion value - AD HOC NEWS
BioMarin Pharmaceutical stock holds near a $12.38 billion value AD HOC NEWS
BioMarin Pharmaceutical (BMRN) Could Be 35% Undervalued Following Profluent AI Collaboration - Simply Wall Street
BioMarin Pharmaceutical (BMRN) Could Be 35% Undervalued Following Profluent AI Collaboration Simply Wall Street
BMRN Q2 2026 Earnings: EPS Beats Estimates by 4% but Shares Slip - Guidance Revision Trend - dars.gov.et
BMRN Q2 2026 Earnings: EPS Beats Estimates by 4% but Shares Slip - Guidance Revision Trend dars.gov.et
BioMarin Pharmaceutical stock holds near its 52-week low - AD HOC NEWS
BioMarin Pharmaceutical stock holds near its 52-week low AD HOC NEWS
BMRN Q2 2026 Earnings: EPS Beats Estimates by 4% but Shares Slip - Revenue Growth Report - dars.gov.et
BMRN Q2 2026 Earnings: EPS Beats Estimates by 4% but Shares Slip - Revenue Growth Report dars.gov.et
BioMarin Pharmaceutical stock weighs VOXZOGO setback against growth - AD HOC NEWS
BioMarin Pharmaceutical stock weighs VOXZOGO setback against growth AD HOC NEWS
BioMarin Pharmaceutical stock falls 1.38 percent on Nasdaq - AD HOC NEWS
BioMarin Pharmaceutical stock falls 1.38 percent on Nasdaq AD HOC NEWS
BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullish - AD HOC NEWS
BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullish AD HOC NEWS
BMRN Q2 2026 Earnings: EPS Tops Consensus by 4.05% as Shares Edge Higher - Preliminary Results - dars.gov.et
BMRN Q2 2026 Earnings: EPS Tops Consensus by 4.05% as Shares Edge Higher - Preliminary Results dars.gov.et
BioMarin Grants Ascendis Global License, Secures Royalty Revenues - TipRanks
BioMarin Grants Ascendis Global License, Secures Royalty Revenues TipRanks